

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

April 28, 2015

<u>Via E-mail</u> John A. Herrmann, III Vice President, General Counsel and Corporate Secretary Novavax, Inc. 9920 Belward Campus Drive Rockville, Maryland 20850

> Re: Novavax, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 20, 2015 File No. 000-26770

Dear Mr. Herrmann:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Daniel Greenspan for

Jeffrey P. Riedler Assistant Director

cc: <u>Via E-Mail</u> Paul M. Kinsella, Esq. John F. Donnelly, Esq. Ropes & Gray LLP